SMi Group reports: Key microbiology speaker interviews released ahead of SMi’s 4th Annual Microbiology West Coast Conference, taking place in two weeks.
Pharmaceutical Solid Dosage Contract Manufacturing Market May Set New Growth Story | BioPharma Solutions, Pillar5 Pharma, Emergent BioSolutions, Haupt Pharma
iCrowd Newswire
12 May 2021, 21:05 GMT+10
The latest analysis released by HTF MI on COVID-19 Outbreak-Global Pharmaceutical Solid Dosage Contract Manufacturing Market Outlook 2021 Survey results sheds light on how investment and competitive landscape is impacted due to significant changes in the COVID-19 Outbreak- Pharmaceutical Solid Dosage Contract Manufacturing Industry. The research coverage includes analysis on companies such as Covance, Althea Technologies, Fresenius Kabi, Mikart, Emergent BioSolutions, Catalent Pharma Solutions, BioPharma Solutions, Abbott Laboratories, Associates of Cape Cod, Pillar5 Pharma, Haupt Pharma, Lyophilization Technology, DPT Laboratories, Cytovance Biologics, Halo Pharmaceutical, Alkermes & Jubilant Life Sciences Limited etc. It is expected that the healthcare and life sciences industry
Share this article
Share this article
EAST FALMOUTH, Mass., April 23, 2021 /PRNewswire/ Associates of Cape Cod, Inc. (ACC), a Seikagaku Group Company, announces the launch of a new, innovative, sustainable recombinant LAL reagent, PyroSmart NextGen™ for Bacterial Endotoxin Testing (BET). The new LAL reagent is sustainably produced using recombinant technology; it is not based on raw materials from animals, unlike traditional LAL reagents which are manufactured using the blood harvested from horseshoe crabs. After years of research and development, the Company has been able to bring a truly sustainable alternative LAL reagent, designed to deliver consistent and reliable quantitation in all BET applications requiring LAL reagents such as testing of water, injectable drugs, vaccines and medical devices.